As the leader and founder of High Content Screening (HCS), Cellomics, Inc. is pleased to be the executive sponsor of the Cambridge Healthtech Institute (CHI) annual High Content Analysis (HCA) and RNAi for Pathway Analysis conferences to be held in San Francisco, February 1-3. With continued growth in the use of high content screening (HCS) and analysis for cell biology, CHI is expecting a remarkable turn out at this year’s conference. Cellomics will also hold its annual User Group meeting and a new RNAi tutorial.
